Compounds modeled on the weight loss blockbusters are also in trials for schizophrenia and Parkinson's disease, among other brain conditions.
Recap by typeshit. Full story at Nature.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A TriNetX study of 4,253 matched patients per group, shown at ACG 2026, found roughly half the MACE risk at one year with resmetirom. Retrospective data, so no causation.
Therapist Zoë Bisbing and novelist Rainbow Rowell describe moms on Ozempic-style drugs pushing daughters to start, and the body-image fights that follow.
Loading…